How to read a PMA supplement

A PMA approval order covers a specific device, built and labeled exactly as described in the application FDA reviewed. Change the device afterward — a material, a software update, a new indication — and you don’t usually start over with a new PMA. You file a supplement, and which of three types it falls into decides how much review is coming.

Why a supplement exists at all

An approved PMA isn’t a license to keep iterating the device however the manufacturer sees fit afterward — it’s approval of a specific device, described down to its materials, design, manufacturing process, and labeling. A device that evolves after approval, which almost every device does eventually, creates a gap between what was approved and what’s actually being made. A supplement is how that gap gets closed on the record, before the changed device reaches the market rather than after.

Three types, three different review experiences

Most changes that affect safety or effectiveness — a significant change in components, materials, design, specifications, software, color additives, or labeling — go through a 180-day supplement, so named because that’s the review clock FDA is working against. The clinical data that supported the original approval is often still applicable here, which is part of what keeps the review faster than a full PMA. A panel-track supplement is a different scale of change: a significant change in design or performance, or a new indication for use, where substantial new clinical data is needed to support it, and where FDA may convene an outside advisory panel the way it would for an original PMA. A narrower real-time option exists for genuinely minor changes — the kind where the sponsor and FDA can work through the question together in a scheduled review rather than a standard written cycle. The type is a judgment about how much the change actually matters, not a formality.

Not the annual report, and not the filing gate

It’s worth keeping a supplement distinct from the other PMA paperwork a device accumulates. A PMA annual report is ongoing postapproval reporting on a device that hasn’t changed its approved design — adverse events, literature, manufacturing status. A refuse-to-file decision is an administrative gate on an original PMA before substantive review even starts. A supplement is neither of those: it’s what gets filed specifically because the approved device is being changed, and it goes straight to substantive review rather than a completeness check.

The device changes; the approval has to catch up to it on the record, not after the fact. Reading 21 CFR 814.39 once, as part of building a habit of reading the regulation itself, is a cheap way to know which of the three conversations with FDA you’re actually about to have.